ET-02
ET-02 is in Phase 1 for androgenetic alopecia, developed by Eirion Therapeutics.
A topical reporting a six-fold hair-count gain over a pooled placebo group after four weeks, in 24 people.
- Developed by
- Eirion Therapeutics
- Current phase
- Phase 1
- Mechanism
- Stem cell activation
- Indications
- Androgenetic alopecia
- Also known as
- RS-5441, ET02
- Last public activity
- No trials on record
- Copy last reviewed
- September 2026
- Record confidence
- Medium
First tests in humans. Answers 'is it safe?', not 'does it work?'.
Uses stem or progenitor cells to regenerate or replace follicle tissue.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
The sponsor describes it as restoring function to hair follicle stem cells that become inactive with age. Nothing further has been published, and this row does not elaborate beyond that description.
Why it matters
The headline number is extraordinary and the trial is tiny: 24 subjects across three US sites, four weeks of once-daily treatment and a final assessment a week later, with no registry record to check the design against. The six-fold figure is the increase in non-vellus hair count relative to a placebo group that pooled the vehicle arm with the lowest ET-02 dose, and the comparison the sponsor draws, more growth than four months of minoxidil, comes from a separate trial rather than a head-to-head randomisation. The 150-patient, six-month Phase 2 the company planned for 2025 has not appeared in any registry.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results — Company release, January 2025
Related programmes
Other programmes in the register with the same mechanism: Stem cell activation.
- RCH-01Phase 2RepliCel Life Sciences
- Epibiotech dermal papilla cell therapyPhase 1/2Epibiotech
- HairClone follicle banking & cell therapyPhase 1HairClone
- OrganTech / Tsuji follicular primordiumPreclinicalOrganTech
- TissUse Smart Hair TransplantPreclinicalTissUse
- Aderans dermal sheath cup cells (Ji Gami)DiscontinuedAderans Research Institute
Cite this page
Hair Pipeline, "ET-02 — development record", hairpipeline.com/pipeline/et-02